{"id":3334,"count":25,"description":"A MedsBase Hepatitis Gy\u00f3gyszerek kateg\u00f3ri\u00e1ja azon or\u00e1lis antivir\u00e1lis szereket foglalja mag\u00e1ban, amelyek a tablett\u00e1kkal kezelhet\u0151 k\u00e9t k\u00fcl\u00f6nb\u00f6z\u0151 kr\u00f3nikus v\u00edrusos m\u00e1jfert\u0151z\u00e9sre haszn\u00e1lhat\u00f3k \u2014 kr\u00f3nikus hepatitis B (HBV)<\/strong> \u00e9s kr\u00f3nikus hepatitis C (HCV)<\/strong> — along with the tenofovir-based combinations used for both HBV suppression and HIV pre-exposure prophylaxis. Each treatment class has its own goal, mechanism and duration. Choosing the right medication starts with knowing which virus you are treating, your kidney function, and whether you are co-infected with HIV.\n\nHepatitis C: 12-week direct-acting antiviral (DAA) cure\nHCV is the only chronic viral hepatitis that current oral therapy can meggy\u00f3gy\u00edthat<\/em>. A direkt hat\u00e1s\u00fa antivir\u00e1lis szerek (DAAs) egyszerre c\u00e9lozz\u00e1k meg a HCV NS5B polimer\u00e1z\u00e1t \u00e9s az NS5A replik\u00e1ci\u00f3s komplex\u00e9t. Az eredm\u00e9ny tart\u00f3s virol\u00f3giai v\u00e1lasz (SVR12) \u2014 HCV RNS 12 h\u00e9ttel az utols\u00f3 tabletta ut\u00e1n nem \u00e9szlelhet\u0151 \u2014 a cirr\u00f3zis n\u00e9lk\u00fcli, kezel\u00e9sre \u00e9rz\u00e9keny betegek 95%-\u00e1ban vagy ann\u00e1l nagyobb ar\u00e1nyban. A kezel\u00e9s 12 h\u00e9tig tart; ha egyszer meggy\u00f3gyult, nincs sz\u00fcks\u00e9g tov\u00e1bbi antivir\u00e1lis kezel\u00e9sre.\n\nHepcinat LP<\/strong><\/a> — sofosbuvir 400 mg + ledipasvir 90 mg, generic Harvoni. First-line for HCV genotypes 1, 4, 5 and 6.\n\n\nHepatitis B: long-term suppression with tenofovir\nUnlike HCV, chronic hepatitis B is currently a manageable infection rather than a curable one. The cccDNA template inside infected hepatocytes is not eliminated by any oral drug, which is why HBV treatment is usually long-term. The goal is undetectable HBV DNA, normal ALT, and prevention of cirrhosis and hepatocellular carcinoma. Two tenofovir formulations dominate guidelines (EASL, AASLD, APASL, WHO):\n\nTenvir<\/strong><\/a> \u2014 tenofovir diszoproxil fum\u00e1r\u00e1t (TDF) 300 mg a Cipla gy\u00e1rt\u00e1s\u00e1ban. 20+ \u00e9v biztons\u00e1gi adattal; el\u0151nyben r\u00e9szes\u00edtett terhess\u00e9g alatt.\nTeravir<\/strong><\/a> \u2014 tenofovir diszoproxil fum\u00e1r\u00e1t 300 mg a Cipla gy\u00e1rt\u00e1s\u00e1ban, alternat\u00edv TDF m\u00e1rka.\nTenvir AF<\/strong><\/a> — tenofovir alafenamide (TAF) 25 mg by Cipla, generic Vemlidy. Same active metabolite as TDF, but ~90% lower plasma exposure: substantially less renal and bone toxicity. Preferred in chronic kidney disease, osteoporosis, age > 60, or pre-existing TDF toxicity.\n\n\nHIV pre-exposure prophylaxis (PrEP) and treatment-combination tablets\nThe same tenofovir backbone, when combined with emtricitabine (FTC), is the standard for HIV pre-exposure prophylaxis — reducing HIV acquisition risk by > 99% when taken daily as directed. These products are listed in this category because TDF alone is also active against HBV; in HBV\/HIV co-infection a single combination tablet covers both. Three branded generics of Truvada are stocked here:\n\nTenvir-EM<\/strong><\/a> \u2014 TDF 300 + FTC 200 a Cipla gy\u00e1rt\u00e1s\u00e1ban.\nRicovir EM<\/strong><\/a> \u2014 TDF 300 + FTC 200 a Mylan gy\u00e1rt\u00e1s\u00e1ban.\nTenof EM<\/strong><\/a> — TDF 300 + FTC 200 by Hetero.\n\nDaily PrEP, the 2-1-1 event-based regimen (cisgender MSM only), or HIV combination treatment all start with the same molecule. Choice between the three brands is largely about manufacturer preference and stock; pharmacology is identical.\n\nChoosing between options\n\n\n\nNeed\nRecommended starting point\n\n\n\nHepatitis C cure (genotype 1\/4\/5\/6)Hepcinat LP, 12-week course.\nChronic HBV, normal kidneys, age < 60Tenvir or Teravir (TDF 300).\nChronic HBV with CKD, osteoporosis, or age > 60Tenvir AF (TAF 25).\nHIV PrEP — daily or 2-1-1Tenvir-EM, Ricovir EM or Tenof EM (TDF\/FTC).\nHBV + HIV co-infectionA TDF\/FTC combination — covers both.\n\n\n\nAll hepatitis B and HIV regimens require baseline workup (HBV DNA or HIV RNA, HBeAg\/HBsAg, eGFR, ALT, hepatitis screening, lipid panel) and ongoing specialist monitoring. Hepatitis C treatment also benefits from hepatologist supervision, especially if there is any cirrhosis or co-medication that interacts with DAAs. MedsBase supplies the medication; clinical monitoring should be set up locally.","link":"https:\/\/medsbase.com\/hu\/hepatitis-medication\/","name":"Hepatitisz gy\u00f3gyszerek","slug":"hepatitis-medication","taxonomy":"product_cat","parent":3223,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product_cat\/3334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product_cat\/3223"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product?product_cat=3334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}